GNI Group Ltd

GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics products. It also develops ETUARY which is in Phase III clinical trial for the treatment of pneumoconiosis, dermatomyositis interstitial lung disease, and systemic sclerosis-associated interstitial lung disease; and F351 which is in Phase III clinical trial for the treatment of chronic hepatitis B liver fibrosis. In addition, the company is involved in the development of ETUARY which is in Phase II clinical trial for the treatment of radiation-induced lung injury with or without immune-related pneumonitis; F573 which is in Phase II clinical trial for the treatment of acute liver failure and acute-on-chronic liver failure; F351 which is in Phase I clinical trial for the treatment of MASH-advanced liver fibrosis; and F230 which is in Phase I clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops CG001419 which is in Phase Ia clinical trial for the treatment of acute and chronic pain; CG001419 which is in Phase Ia clinical trial for the treatment of solid tumors; and CG009301 which is in Phase Ia clinical trial for the treatment of leukemia and MYC+ cancers. The company was incorporated in 2001 and is headquartered in Chuo, Japan.